86 results about "Androstenes" patented technology

The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3β,17-diol or androstane-3β-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3β-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor-(PPAR) is produced.

The invention discloses a synthesis method of 17alpha-hydroxyl progesterone, which comprises the steps of by taking 4-androstene-diketone as a starting raw material, carrying out vyanation via acetone cyanohydrin, protecting 3carbonyl by using triethyl orthoformate and ethyl alcohol, protecting 17hydroxy by using butyl vinyl ether, and carrying out hydrolysis after Grignard reaction to generate the 17alpha-hydroxyl progesterone. According to the synthesis method, the cost is reduced, the environment pollution is decreased, the reaction time is shortened, the aftertreatment process of the industrial production is simplified, the production time and cost are greatly saved, the productivity is improved and convenience is brought to the industrial implementation. Compared with the traditional process, the synthesis method has the characteristics of low raw material cost, simple and convenient method, high yield, good selectivity, mild reaction condition, small pollution and applicability to industrial production; and the method is stable and easy to realize.

The invention discloses a high-sensitivity nanometer cobalt oxide-doped talampicillin molecular imprinting electrochemical sensor and a preparation method thereof. Talampicillin serves as a template molecule, N-tert-butyl-2alpha-hydroxyl-5alpha-androstene-3-ketone-17beta-formamide serves as a functional monomer, azodiisobutyronitrile serves as an initiator, nanometer cobalt oxide serves as a doping agent, and maleated rosin ethylene glycol acrylate synthesized by taking rosin as a raw material serves as a crosslinking agent, so as to prepare a high-sensitivity nanometer cobalt oxide-doped talampicillin molecular imprinting electrochemical sensor. The analytical method is simple and practical, and the defects that the previous analytical method is complex, expensive in equipment and low in sensitivity are overcome.

The invention discloses a synthesis method of finasteride, which comprises the following steps that: taking inexpensive luteosterone and the like as the raw materials to finally prepare finasteride through 6 steps of synthetic reaction, i.e. the synthesis of 3- carbonyl-4- androstene-17beta-carboxylic acid, the synthesis of N-tertiary-butyl-3- carbonyl-4- androstene-17beta-formamide, the synthesis of N-tertiary-butyl-5- carbonyl-17beta- carbamoyl-A-lost carbon-3,5-cracking- androstane-3-acid, the synthesis of N-tertiary-butyl-3-carbonyl-4- aza-5- androstene-17beta-formamide, the synthesis of N-tertiary-butyl-3- carbonyl-4- aza-5alpha- androstane-17beta- formamide, and the synthesis of finasteride. The synthesis process has the advantages of inexpensive and easily available raw materials and stable yield, is applicable to industrial production, and the product quality meets the pharmacopeia standards.

The invention discloses a preparation method of a compound 19-desmethyl-4-androstene-3,17 diketone, comprises the following step of by taking compounds of 5alpha-chloro-3beta-hydroxy-6beta and 19beta-epoxy-androstane-17-ketone as raw materials, and carrying out oxidation reaction on the compounds of 5alpha-chloro-3beta-hydroxy-6beta and 19beta-epoxy-androstane-17-ketone as well as an intermediate compound 19-hydroxy-4-androstene-3,17-diketone with N-halogenated amide oxidant in a mixed solution of an organic solvent and an alkaline buffer solution in the presence of a catalytic amount of 2,2,6,6-tetramethylpiperidine-N-oxide (TENPO) in the mild condition. In the two steps of oxidation reaction, the catalytic amount of 2,2,6,6-tetramethylpiperidine-N-oxide and the N-halogenated amide oxidant are both adopted to replace a mixed solution of chromium trioxide, sulfuric acid and water. In the oxidation method, without using the chromium trioxide, the use of carcinogenic substances are avoided being used, limitation by environmental protection is avoided and a great amount of wastes containing heavy metals in preparation are avoided being generated and accumulated, thereby no money and labor is consumed for removing the wastes.

The invention discloses a nanometer cobaltous oxide doped micronomicin molecular imprinting electrochemical sensor with the high sensitivity and a preparation method of the sensor. The preparation method is characterized in that micronomicin is utilized as a template molecule, 20(s)-O-3beta-hydroxyl-5-androstene-17beta-acyl camptothecin is utilized as a functional monomer, azodiisobutyronitrile is utilized as an initiator, nanometer cobaltous oxide is utilized as a doping agent, and maleated rosin crylic acid gylcol ester which is compounding by taking rosin as a raw material is utilized as a cross-linking agent, so that the nanometer cobaltous oxide doped micronomicin molecular imprinting electrochemical sensor with the high sensitivity is prepared, an analytical method is simple and practical, and the disadvantages that an existing analytical method is complex, equipment is expensive, and the sensitivity is low are overcome.

The present invention relates to the field of cancer, and in particular hormone dependent cancers including, but not limited to prostate, breast, endometrial, ovarian, thyroid, bone, and testis. The present invention also relates to the use of steroid analogues, and in particular analogues of Δ5-androstene-3-β, 17α-diol, and its epimer Δ5-androstene-3-β, 17β-diol for the treatment and prevention of cancer.

The invention provides a preparation method of 6a-methyl hydrocortisone. The preparation method comprises the steps that hydrocortisone prepared from 4-androstene-3,17-dione (called as 4AD for short) is adopted as a raw material to generate an acid catalytic reaction with triethyl orthoformate in an organic solvent, and etherate 3-ether enol hydrocortisone is obtained; the etherate generates a Manlixi reaction with N-methylaniline and formaldehyde in an organic solvent, and a methylene product 6-methylene hydrocortisone is obtained; the methylene product generates a catalytic hydrogenation reaction in an organic solvent, and 6a-methyl hydrocortisone is obtained. Compared with a production method achieved by taking a mold removal product obtained by processing diosgenin as a raw material, the method for producing 6a-methyl hydrocortisone has the advantages that raw material sources are wide, the processes are economical and environmentally friendly, production operation is easy and convenient, the synthetic route is short, and the product yield is high; by producing 6a-methyl hydrocortisone through the method, the production cost is reduced by 40%-50% compared with a traditional method; the solvents used in production can be recycled and cyclically reused, and implementation of industrialized production is promoted.

The invention discloses a nano cobaltous oxide-doped minocycline hydrochloride molecular imprinting electrochemical sensor with high sensitivity and a preparation method of the nano cobaltous oxide-doped minocycline hydrochloride molecular imprinting electrochemical sensor. The minocycline hydrochloride is taken as a template molecule, 20(s)-O-3beta-acetoxyl-5-androstene-17beta-acyl camptothecin is taken as a functional monomer, azodiisobutyronitrile is taken as an initiator, nano cobaltous oxide is taken as a dopant, and maleic rosin ethylene glycol acrylate synthesized from rosin as a raw material is taken as a cross-linking agent, so as to prepare the nano cobaltous oxide-doped minocycline hydrochloride molecular imprinting electrochemical sensor with high sensitivity. The analysis method is simple and practical, and the defects that the traditional analysis method is complicated, expensive in equipment, and low in sensitivity are overcome.

This invention discloses a synthesis technology of finasteride, it takes 3-oxo-4-androstene-17 beta-carboxylic acid methyle as raw material, and synthesizes finasteride through the following five steps, (a). hydrogen peroxide; (b). cyclization; (c). catalyzed hydrogenation reduction; (d). ester-amide condensation into amide; and (e). oxidizing to form double bond. Compare with the existing technology, this technology has short route, high efficiency, simple operation and low cost.

The invention relates to the field of pharmaceuticals for tumor-inhibitory effects. The 5-androstene 3β,17α diol (αAED) and 5-androstene 3β,17β diol (βAED), their esters and ethers, are taught herein to achieve tumor-inhibiting effect. The invention also relates to the field of pharmaceuticals for tumor-inhibitory effects and the use of 5-androstene 3β,7β,17β triol (βAET), 5-androstene 3β,7α,17β triol (αAET or 17α-AET) and their esters and ethers, are taught herein to achieve tumor-inhibiting effect.

A process for synthesizing N-tert-butyl-3-carbonyl-4-a2Q-5 alpha-androst-1-ene-17 beta-formamide, that is phenandrostamine, includes such steps as providing 4-androstene-3, 17-dione as raw material, oxidizing for opening loop to obtain 5, 17-dicarbonyl-3, 5-openloop-androst-3-acid, reacting on ammonium acetate for closing loop to obtain 4-azasterol compound, cyanoalcoholizing, dewatering, Ritter reaction on tert-butanol, hydrogenating and dehydrogenating.

The invention discloses a method for processing dehydroepiandrosterone mother liquor objects. DHEA, 3alpha-hydroxide radical-5-androstene-17-ketone and 3, 17-diketal objects can be obtained through column chromatography isolation; then the obtained 3alpha-hydroxide radical-5-androstene-17-ketone and the obtained 3, 17-diketal objects synthesize a starting material 4-AD. By means of the method, the purity of the dehydroepiandrosterone (DHEA) obtained through the column chromatography isolation is larger than or equal to 99.5%, and the DHEA total yield is larger than or equal to 75%; materials obtained through the column chromatography isolation can synthesize the 4-AD, reusing can be carried out, and the using rate is high; pollution of hormone waste to the environment is reduced.

The invention provides a method for preparing 19- nor-4-androstene-3, 17-diketone. The preparation method comprises the following step: with a compound I as a raw material, carrying out a Grignard reaction, an oxidation and ring-closure reaction and a reduction and ring-closure reaction, and the reaction route is shown as follows. The starting raw material of the preparation method is relatively cheap, the product yield is high and the production cost can be saved. The formula is described in the description.

The invention relates to a method for preparing 17alpha-hydroxyprogesterone. The17alpha-hydroxyprogesterone is prepared by taking 17beta- cyano-5-androstene-17-ol-3,3-diethylene ketal (referred as an intermediate II) as a raw material and dimethylzinc or methylzinc chloride as a reagent; the content of the 17alpha-hydroxyprogesterone by HPLC is above 99.5% and the weight yield is 83-87%. The method comprises the following steps of dissolving the intermediate II in an organic solvent, adding lithium chloride as a catalyst, stirring, raising the temperature to 40-80 DEG C, dropwise adding a toluene solution of dimethylzinc or methylzinc chloride of which the concentration is 2M, and continuing to complete the reaction; and then adding an ammonium chloride solution of which the concentration is 25% to destruct an organic zinc reagent, separating the aqueous layer out and extracting, merging the organic layer and the extract and concentrating the solvent to near dryness, and then adding lower alcohol, stirring, raising the temperature to 40-60 DEG C, adding the acid of which the concentration is 2M, hydrolyzing, adjusting the pH value with a weak base after the reaction is completed, evaporating 90% of the solvent out, adding tap water, cooling and crystallizing to obtain a crude 17alpha-hydroxyprogesterone product; and then carrying out reflux decolorizing on the crude product with activated carbon by virtue of alcohol, and refining to obtain the commercial grade 17alpha-hydroxyprogesterone. The 17alpha-hydroxyprogesterone produced by the method disclosed by the invention has the advantages of good purity and high yield and is economic and environment-friendly, and the solvent can be recycled.

The invention discloses the synthesis and application of four new conjugates of camptothecin-steroid. The four new conjugates of camptothecin-steroid are: 1) the name of the first new conjugate is 20 (S)-O-3 beta-hydroxy-5-androstene-17 beta-acyl camptothecin, CPT-1 for short; 2) the name of the second new conjugate is 20 (S)-O-3 beta-acetoxy-5-androstene-17 beta-acyl camptothecin, CPT-2 for short; 3) the name of the third new conjugate is 20 (S)-O-androst-4-alkene-17 beta-acyl camptothecin, CPT-3 for short; 4) the name of the forth new conjugate is 20 (S)-O-4-aza-5 alpha-androst-3-ketone-17 beta-acyl camptothecin, CPT-4 for short; By employing EDCI-DMAP coupling method, all the four new conjugates of camptothecin-steroid are synthesized based on raw materials of camptothecin and four steroid acids. The compounds of the invention have good antineoplastic activity, and great prospect in pharmaceutical development.

The invention relates to a method for synthesizing drospirenone and belongs to the field of pharmaceutical chemicals, which comprises: reacting a 3beta,5beta-dyhydroxy-6beta,7beta,15beta,16beta-imethylene-17alpha-(3'-hydroxypropyl)-androstene-17ol compound serving as a raw material in dichloromethane in the presence of dichlorodimethylhydantoin, potassium bicarbonate and crown ether, which serve as catalysts, to obtain an 3-oxo-5beta-hydroxy-6beta, 7beta,15beta,16beta-dimethylene-17alpha(spiro)butyrolactone intermediate; removing excessive oxidant by using a small amount of sodium sulfite, filtering the solution, adding a certain amount of phosphorus pentoxide into solution of dichloromethane for dehydration, adding water for washing the reaction product for one time at the end ( detected by thin-layer chromatography) of the reaction and washing the reaction product for one time with saturated solution of sodium bicarbonate; drying the reaction product with anhydrous sodium sulfate, filtering the reaction product, distilling and recovering solvent and crystallizing the solid with water solution (in a volume ratio of 3:1) of methanol; and finally, recrystallizing the obtained solid with isopropylacetate to obtain a qualified drospirenone product. The synthesis yield of the method is about 67 percent. The reaction is mild and easy to operate and consumes a small amount of organic solvent.

Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+,K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

The invention provides a method for synthesizing 17alpha-hydroxyprogesterone.17beta-cyano-5-androstene-17-alcohol-3,3-ethylene dihydroxy ketal (an intermediate II for short) is adopted as a raw material, and cheap cyclohexanone cyanohydrin is adopted as an inhibitor of a main impurity methyltestosterone. Due to the fact that a cyclohexanone cyanohydrin structure is similar to a D-loop structure in the molecular structural formula of the intermediate II and can replace a D loop to react with OH<1> in a Grignard reaction system, generated methyltestosterone is greatly reduced. Under the catalytic action of anhydrous lithium chloride or CuCl, the reaction temperature is reduced to -15 DEG C to -10 DEG C, and other generated impurities can be reduced at the low temperature. Therefore, the product quality is improved by controlling Grignard reaction conditions, the content of crude HPLC can reach 98% or above, and the total weight yield ranges from 84% to 88% and is improved by 10% to 14% compared with a traditional process.

The invention relates to a preparation method of 5alpha-androstane-3,17-dione. The method specifically comprises the following steps: 1, carrying out an etherification reaction on 4-androstenedione, triethyl orthoformate and anhydrous ethanol in the presence of an etherification catalyst, and performing post-treatment after the etherification reaction is completed in order to prepare a compoundwet 3-ethoxy-3,5-androstadien-17-one; 2, adding a the wet 3-ethoxy-3,5-androstadien-17-one into a methanol-dichloromethane mixed solvent, performing uniform stirring, adjusting the pH value of the obtained solution, carrying out a catalytic hydrogenation reaction under the action of a palladium-carbon catalyst, and filtering out the catalyst after the reaction is finished in order to obtain a 3-ethoxy-3-androstene-17-one solution; and 3, carrying out a hydrolysis reaction on the 3-ethoxy-3-androstene-17-tone solution and an acid, removing the solvent after the hydrolysis reaction is finished,and carrying out filtering, water washing and drying to obtain the 5alpha-androstane-3,17-dione. The method has the advantages of short process route, easily controlled production process, environmental friendliness, low production cost, and suitableness for industrial large-scale production.

This invention relates to processes for the preparation of novel , substituted steroid compounds of Formula 1, wherein R1 is H or -COR2; R2 is C1-C6 alkyl or Ct-C6 alkoxy; Z1 is CH2, or wherein OR3 is in the alpha configuration; R3 is H or -COR2; Z2 is -CH-; or Z1 and Z2 may be taken together to form a carbon-carbon double bond; Q is or Y is -CN, -CH2-CH=CH2, C1-6- Alkyl C1-6 alkyl CHR4C (O)Ar, or CHR4 C (O)XC1-6 alkyl; CHR4(O)XAr, or CHR4 HC(O)XC1-6 alkyl; where R4 = O C1-6 alkyl or aryl X=O or S.

The invention discloses a method for preparing 19-nor-4-androstene-3,17-dione. The method comprises the following steps: taking a compound 1 as an initial raw material, carrying out a hydrolysis reaction, a hydrogenation reaction and condensation reaction so as to obtain 19-nor-4-androstene-3,17-dione, wherein the reaction formula is as shown in the specification. According to the method disclosed by the invention, a high-purity 19-nor-4-androstene-3,17-dione product is obtained at the total molar yield of 83% or higher, and the method is low in cost, green, environmental-friendly and suitable for industrial production.

The invention discloses a method for preparing 17beta-carboxyl-4-androstene-3-ketone. The method comprises a step (a) of enabling 3-ethoxy androstane-3,5-diene-17-ketone to react with tosylmethyl isocyanide in an organic solvent under the conditions of strong base, and obtaining a first intermediate product with a formula (II) structure; a step (b) of hydrolyzing the first intermediate product under the acidic conditions, and obtaining 17beta-carboxyl-4-androstene-3-ketone. The preparation method has the advantages of being low in cost and high in yield; and the formula (II) is as follows.

The invention provides a method for preparing 3-carbonyl-4-aza-5-androstene-17 beta carboxylic acid derivative 01 from mother solution reclaimed materials of a hydrogenation reaction. The method comprises the following steps: (1) dissolving the mother solution reclaimed materials, which are obtained by preparing 3-carbonyl-4-aza-5 alpha-androstane-17 beta carboxylic acid derivative 03 by performing hydrogenation reaction on 3-carbonyl-4-aza-5-androstene-17 beta carboxylic acid derivative 01, into glacial acetic acid, and adding a palladium-carbon catalyst, introducing oxygen, pressurizing and heating to perform dehydrogenation reaction; (2) cooling the reaction system, filtering to obtain a filter cake, washing the filter cake by using glacial acetic acid, and performing suction filtration until the filter cake is dried, thereby obtaining a waste palladium-carbon filter cake; and (3) performing vacuum concentration on a filtrate until the filtrate is almost dried, adding methanol into the system, performing freezing crystallization, performing swinging filtration to obtain a filter cake, washing the filter cake by using methanol, performing swinging filtration until the filter cake is dried, and drying to obtain the 3-carbonyl-4-aza-5-androstene-17 beta carboxylic acid derivative 01. By adopting the method provided by the invention, wastes are recycled to synthesize an important medical intermediate, the cost is reduced, and pollution is reduced. Original auxiliary materials are simple, easily available and recyclable, and the process is simple and is suitable for industrial implementation.